Mayne Pharma Group Ltd has released a press release.
Mayne Pharma to restate US dermatology net revenue for FY22
Filed with ASX ·
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- Mayne Pharma and Mithra announce US launch of HALOETTE, a generic version of NUVARING
- Mayne Pharma provides update on capital management timeline
- MYX completes TherapeuticsMD product licensing transaction
- MYX signs license agreement for womens health products
- AGM presentation and business and trading update
Later from Mayne Pharma
- Mayne Pharma announces sale of US retail generics business
- 2022 Half Year Media Release
- 2023 Half Year Investor Presentation
- Mayne Pharma announces cancellation of capital return
- Update on sale of US retail generics portfolio
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma